EMEA-001635-PIP03-17

Key facts

Active substance
Tanezumab
Therapeutic area
Pain
Decision number
P/0070/2018
PIP number
EMEA-001635-PIP03-17
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Treatment of chronic musculoskeletal pain
  • Treatment of chronic pain (excluding musculoskeletal pain)
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
Pfizer Limited

Tel. + 44 1304646607
E-mail: pip_enquiries@pfizer.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating
Average
1 rating